CO-ADD Offers Antibiotic ESKAPE Screens

Rich Taylor

The Community forOpen Antimicrobial Drug Discovery (CO-ADD) is a Wellcome Trust funded, non-for-profit, openframework for discovery and development of new therapies against multidrug-resistant (MDR) bacteria ( based at The University of Queensland in Australia.

CO-ADD will perform primary antibacterial screening for academic research groups as a free service and makes no claims on results or IP.
In the primary screening they test against five key ESKAPE pathogens, E. coli, K.pneumonia, A.baumannii, P.aeruginosa, S.aureus (MRSA) and 2 fungi (C. neoformans and C. albicans). Hits will be further analyzed with specific panels that include MDR, Pan-resistant bacterial strains and clinical isolates as well as general cytotoxicity. Only requires 1 mg and the provider of the compound does not need to provide a structure. The Wellcome Trust asks that after 18 months, the participant should make the results available to the community (CO-ADD or chEMBL database).

For more information read about the CO-ADD in ACS Chemical Biology.